Clear Search sequence regions
Bookmark Forward

QuickView for Atazanavir (compound)


PubChem
Name: atazanavir
PubChem Compound ID: 11520467
Molecular formula: C38H52N6O7
Molecular weight: 707.874 g/mol
DrugBank
Identification
Name: atazanavir
Name (isomeric): DB01072
Drug Type: small molecule
Synonyms:
Atazanavir sulfate; ATV; ATZ; BMS-232632
Brand: Reyataz, Latazanavir, Zrivada
Category: HIV Protease Inhibitors, Anti-HIV Agents, Protease Inhibitors
CAS number: 198904-31-3
Pharmacology
Indication: Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
Pharmacology:
Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and i...
show more »
Mechanism of Action: Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.
Absorption: Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.
Protein binding: 86% bound to human serum proteins (alpha-1-acid glycoprotein and albumin). Protein binding is independent of concentration.
Biotransformation: Atazanavir is extensively metabolized in humans, primarily by the liver. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.
Half Life: Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).
Affected organisms: Human Immunodeficiency Virus
Interactions
Food interaction:
Administration with food reduces pharmacokinetic variability.
Food increases product absorption.
Drug interaction:
TeniposideThe strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed.
BromazepamAtazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
ErlotinibThis CYP3A4 inhibitor increases levels/toxicity of erlotinib
AtorvastatinAtazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
Sodium bicarbonateThis gastric pH modifier decreases the levels/effect of atazanavir
show more »

Targets


Enzymes


Transporters